Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$611.34
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
330.3
2026-03-01
M2 Money Supply
$22.7T
2026-03-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 101.8; M2 money supply is $22.7T; CPI index stands at 330.3.
SWOT Analysis — REGN
Inflationary BoomStrengths
Revenue: $5.9B (+20.8% YoY) — Revenue grew 21% — the company sold more goods or services than the prior year.
Operating Cash Flow: $5.0B (+12.6% YoY) — Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
EPS (Diluted): $41.48 (+8.2% YoY) — Earnings per share rose 8% — each share earned more.
Total Assets: $40.6B (+7.4% YoY) — Total assets grew 7% — the company's resource base expanded.
Weaknesses
R&D spending is 100% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
Net Income: $4.5B (+2.1% YoY) — Profit grew 2% — the company kept more of each dollar earned.
Threats
No significant threats flagged.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Revenue
$5.9B
was $4.9B
Revenue grew 21% — the company sold more goods or services than the prior year.
Operating Cash Flow
$5.0B
was $4.4B
Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
EPS (Diluted)
$41.48
was $38.34
Earnings per share rose 8% — each share earned more.
Total Assets
$40.6B
was $37.8B
Total assets grew 7% — the company's resource base expanded.
Net Income
$4.5B
was $4.4B
Profit grew 2% — the company kept more of each dollar earned.
Risk Flags
0 high · 0 medium · 1 low- ○ Low
R&D spending is 100% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade REGN
Links open broker research pages. Not an endorsement or recommendation.
Research REGENERON PHARMACEUTICALS, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.